A Study of the Usefulness & Usability of a Healthcare IT System for Managing Multi-morbidity and Poly-pharmacy
NCT ID: NCT03834207
Last Updated: 2019-02-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
672 participants
INTERVENTIONAL
2018-10-01
2020-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A New Organisation of Clinic for Multimorbidity and Polypharmacy
NCT06735339
A Usability Study of a Tele-health Service for Patients With Peripheral Arterial Disease.
NCT05619835
Evaluation of a Drug Interactions Software to Limit Polypharmacy
NCT03901820
MultiPAP Plus: Improving Prescription in Primary Care Patients With Multimorbidity and Polypharmacy
NCT04147130
Multi-PAP: Improving Prescription in Primary Care Patients With Multimorbidity and Polypharmacy
NCT02866799
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The main research question is - "Is the use of a personalised ICT tool that facilitates coordinated care planning, treatment optimisation and patient self-management acceptable to patients with multiple long term conditions and their team of health professionals?".
The 1st phase has focused on the development \& testing of the system. The 2nd phase will involve a 12 month pilot (Feb 17-Jan 18) with max 602 patients (+/- the support of their informal care givers), and a minimum of 62 healthcare professionals in 3 European pilot sites in the UK, Sweden \& Spain. An evaluation will be conducted using healthcare/treatment data \& the completion of questionnaires by the study participants.
The C3-Cloud project structure is as follows:- Funded by the EC; Co-ordinated by Warwick University; 12 European partners involved, supplying technical, clinical \& research expertise. These partners are based in the UK, Spain, Sweden, France, Turkey, Finland \& Germany; and 3 European pilot sites involved in the study - Basque Country in Spain, Region Jamtland in Sweden and South Warwickshire in the UK.
The C3-CLOUD system consists of the following 2 integrated components. (i) C3DP - this component will be used by healthcare professionals in all 3 pilot sites to manage the care of the study patients. This system records e.g. patient identifiers, contact information, diagnoses, medication, treatments, encounters, risk factors, goals \& activities for the patients etc. It also provides professionals with a clinical decision support module. (ii) a Patient Empowerment Platform (PEP) - used by patients (\& carers where applicable) so that they can view \& update their care plan. Patients can record information about themselves, their condition and their care, can view training materials \& upload readings such as blood pressure etc. PEP also automatically takes information from the C3DP system above.
The study is aiming to recruit a minimum of 602 patients to the C3-CLOUD pilot study across all 3 pilot sites. Informed consent to participate in the study will be obtained. The patients must be aged 55+ and have at least 2 or more of the following chronic diseases - diabetes type 2, mild to moderate heart failure, moderate kidney failure and mild to moderate depression. They must also have a sufficiently high level of IT understanding and access to a suitable device/the internet, or must nominate a carer, family member or friend who does.
The patients who are recruited will receive care and treatment using the C3-CLOUD system and will have identifiable data collected about them by healthcare professionals in C3DP, and will use, and provide information about themselves, in the PEP system.
A separate cohort of max 602 patients will be identified retrospectively from local health records at the end of the study to create a 'control' group. These patients will match the same inclusion criteria. However, this control group will have no active role in the study and only their anonymised data will be utilised so that resource utilisation, medication use etc, can be compared for the two groups over the same period.
In the UK, the system will be used by a cross-section of healthcare professionals (minimum 62) across the 3 pilot sites. These will be the healthcare professionals who are most likely to be involved ordinarily in treating the patients during the study.
In addition to the clinical data captured above, the intervention group patients, their carers and the healthcare professionals involved in the project will participate in a series of system/project evaluations before, during and after the study. This will be done through anonymised questionnaires.
Healthcare utilisation \& outcome data will be collected about intervention AND control group patients from local health records systems in an anonymised format. Evaluation data for the intervention group patients will also be extracted from the C3-Cloud system itself in an anonymised format.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intervention Group
Use of the C3-Cloud IT system
Use of the C3-Cloud IT system
Patients who are recruited to the intervention arm will use the C3-Cloud system during the pilot study.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Use of the C3-Cloud IT system
Patients who are recruited to the intervention arm will use the C3-Cloud system during the pilot study.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* They are multimorbid patients that suffer from two or more of the following four conditions in various disease combinations (two conditions set as the minimum threshold):-
* Diabetes type 2
* Renal Failure with eGFR/GFR 30 - 59 (measured or estimated glomerular filtration rate)
* Heart Failure in compliance with NYHA I-II (New York Heart Association classification of heart failure)
* Mild or moderate depression
* They still live and generally plan on living in their home (or in the community) for the 12-month trial duration.
* They or their informal caregiver pass the ICT Handling Self-Check (see Deliverable D10.4, Annex 8.3) (i.e. they have access to and some familiarity with the use of ICT).
* They, or their informal caregiver, have stable access to the internet and at least one of the following devices readily available to use the C3-Cloud components: Computer; Notebook; Smartphone; Tablet. This includes the use of Internet Browsers to open the C3-Cloud patient dashboards online.
* They are able to provide informed consent.
* They are aged 54 or below
* They suffer from any of the following conditions:
* Severe Renal Failure with eGFR/GFR \<30
* Severe Heart Failure in compliance with NYHA III-IV
* Severe depression
* They have other debilitating conditions that impair their decision making capability or their life expectancy (e.g. end-of-life patients or cancer patients)
* They or their informal caregivers do not pass the ICT Handling Self-Check (i.e. they do not have access to suitable IT devices and do not have some familiarity with the use of ICT).
* They have disabilities or other health conditions that would prevent their active involvement in the study project or which prevent them from carrying out essential functions of the trial.
* They live in a care institution, for instance in a residential home or nursing home.
* Their health care expenses are covered by a private insurance: in the C3-Cloud pilot sites, private insurances have no data exchange with EHRs.
* They do not speak the regional language: English for SWFT; Spanish for the Basque country; Swedish for RJH
* They are unable to provide informed consent for study participation.
Patients with further chronic diseases and other co-morbidities or symptoms, for example, frailty, sleeping problems, malnourishment or anxiety, will not be excluded from recruitment. Informal caregivers who pass the ICT Handling Self-Check can substitute for the patient if the patient does not pass the ICT Handling Self-Check - the patient-informal caregiver pair can then still be recruited.
* They are aged 17 or below
* They do not have some familiarity with the use of ICT or do not have the capability to help the patient out with ICT usage if necessary.
* They do not have stable access to the internet and at least one of the following devices readily available to use the C3-Cloud components: Computer; Notebook; Smartphone; Tablet. This includes the use of Internet Browsers to open the C3-Cloud patient dashboards online.
* They are not available most of the time in person or via telephone, email, SMS or other means as to respond to calls for help.
* They have debilitating conditions that impair their decision-making capability.
* They do not speak the local language: English for SWFT; Spanish for the Basque country; Swedish for RJH
* normally be involved in the selected patients care
* open to new ways of working, specifically as part of a MDT (including GPs; consultant nurses or specialist nurses; district nurses; social workers; consultants; physiotherapists or pharmacists)
* open to the use of new technology: MDT members do not have to be technologically knowledgeable but they should be willing to learn how to use technology to support their work.
Exclusion Criteria
55 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Warwick
OTHER
Biosistemak Institute for Health Systems Research
OTHER
Medixine
UNKNOWN
SRDC
UNKNOWN
Institut National de la Santé Et de la Recherche Médicale, France
OTHER_GOV
Eurorec
UNKNOWN
Empirica
UNKNOWN
Örebro University, Sweden
OTHER
Osakidetza
OTHER
Region Jämtland Härjedalen
OTHER
Cambio Healthcare
UNKNOWN
Dr Christopher Marguerie
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr Christopher Marguerie
Consultant Rheumatologist/Associate Medical Director for Research
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Theodoros N. Arvanitis
Role: STUDY_CHAIR
University of Warwick
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Osakidetza
Vitoria-Gasteiz, Araba, Spain
Region Jamtland Harjedalen
Östersund, , Sweden
South Warwickshire NHS Foundation Trust
Warwick, Warwickshire, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
von Tottleben M, Grinyer K, Arfa A, Traore L, Verdoy D, Lim Choi Keung SN, Larranaga I, Jaulent MC, De Manuel Keenoy E, Lilja M, Beach M, Marguerie C, Yuksel M, Laleci Erturkmen GB, Klein GO, Lindman P, Mar J, Kalra D; C3-Cloud Research Team; Arvanitis TN. An Integrated Care Platform System (C3-Cloud) for Care Planning, Decision Support, and Empowerment of Patients With Multimorbidity: Protocol for a Technology Trial. JMIR Res Protoc. 2022 Jul 13;11(7):e21994. doi: 10.2196/21994.
Related Links
Access external resources that provide additional context or updates about the study.
C3-Cloud Website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
689181
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.